Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12Q-001/68
C12N-015/10
출원번호
US-0048905
(2013-10-08)
등록번호
US-9481912
(2016-11-01)
발명자
/ 주소
Fischer, Gerald W.
Daum, Luke T.
출원인 / 주소
Longhorn Vaccines and Diagnostics, LLC
대리인 / 주소
Remenick PLLC
인용정보
피인용 횟수 :
0인용 특허 :
149
초록▼
The invention is directed to compositions and methods for isolating, detecting, amplifying, and quantitating pathogen-specific nucleic acids in a biological sample. The invention also provides diagnostic kits containing specific amplification primers, and labeled detection probes that specifically b
The invention is directed to compositions and methods for isolating, detecting, amplifying, and quantitating pathogen-specific nucleic acids in a biological sample. The invention also provides diagnostic kits containing specific amplification primers, and labeled detection probes that specifically bind to the amplification products obtained therefrom. Also disclosed are compositions and methods for the isolation and characterization of nucleic acids that are specific to one or more pathogens, including for example Influenza virus and Mycobacterium tuberculosis, from a wide variety of samples including those of biological, environmental, clinical and/or veterinary origin.
대표청구항▼
1. A method for detection of a microorganism in a biological sample comprising: contacting the biological sample to the composition to form a mixture, said composition comprising as components; a thermostable polymerase present in an amount from about 0.05 U to about 1 U;a mix of deoxynucleotide tri
1. A method for detection of a microorganism in a biological sample comprising: contacting the biological sample to the composition to form a mixture, said composition comprising as components; a thermostable polymerase present in an amount from about 0.05 U to about 1 U;a mix of deoxynucleotide tri phosphates comprising about equivalent amounts of dATP, dCTP, dGTP and dTTP, collectively present in the composition at a concentration of about 0.1 mM to about 1 mM;a chelating agent selected from the group consisting of ethylene glycol tetraacetic acid, hydroxyethylethylenediaminetriacetic acid, diethylene triamine pentaacetic acid, N,N-bis(carboxymethyl)glycine, ethylenediaminetetraacetic, citrate anhydrous, sodium citrate, calcium citrate, ammonium citrate, ammonium bicitrate, citric acid, diammonium citrate, potassium citrate, magnesium citrate, ferric ammonium citrate, lithium citrate, and any combination thereof, present in the composition at a concentration of about 0.01 mM to about 1 mM;a PCR osmolarity agent selected from the group consisting of N,N,N-trimethylglycine (betaine), dimethyl sulfoxide (DMSO), foramide, glycerol, nonionic detergents, polyethylene glycol, tetramethylammonium chloride, and any combination thereof, present in the composition at a concentration of about 1 mM to about 1 M;an albumin selected from the group consisting of bovine serum albumin, human serum albumin, goat serum albumin, mammalian albumin, and any combination thereof, present in the composition at a concentration of about 5 ng/ml to about 100 ng/ml;at least two salts, the first being a potassium salt selected from the group consisting of potassium chloride and potassium glutamate and the second being a magnesium salt selected from the group consisting of magnesium chloride and magnesium sulfate, collectively present in the composition at a concentration of about 50 mM to about 1 M;one or more dyes; anda buffer selected from the group consisting of tris(hydroxymethyl) aminomethane (Tris), citrate, 2-(N-morpholino)ethanesulfonic acid (MES), N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 1,3-bis(tris(hydroxymethyl) methylamino)propane (Bis-Tris), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), N,N-bis(2-hydroxyethyl) glycine (Bicine), N-[tris(hydroxymethyl)methyl]glycine (Tricine), N-2-acetamido-2-iminodiacetic acid (ADA), N-(2-acetamido)-2-aminoethanesulfonic acid (ACES), piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), bicarbonate, phosphate, and any combination thereof, present in the composition at a concentration of about 1 mM to about 1 M and with a pH of about 6.5 to about 9.0;wherein the components are combined with nuclease-free water;performing multiple thermal cycling steps on the mixture with a pair of PCR primers to form an amplification product that is derived from the nucleic acid that is specific for the microorganism, wherein one primer of the pair of the PCR primers comprises the nucleic acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5, and the other primer of the pair of PCR primers comprises the nucleic acid sequence of SEQ ID NO 3 or SEQ ID NO: 6; anddetecting the presence or absence of the amplification product to determine the presence or absence of the microorganism in the biological sample. 2. The method of claim 1, further comprising detecting an amplified sequence of a control nucleic acid and determining the quality or quantity of amplification which occurred from the multiple thermal cycling steps. 3. The method of claim 1, wherein the biological sample comprises biological material obtained from an individual. 4. A method of providing for detection of a microorganism in a biological sample comprising: providing a PCR-ready composition containing as components: a thermostable polymerase;a mix of deoxynucleotide tri phosphates comprising about equivalent amounts of dATP, dCTP, dGTP and dTTP;one or more chelating agents;one or more PCR osmolarity agents;one or more albumin proteins;one or more salts;one or more dyes; andone or more buffers present in the composition at a pH of about 6.5 to about 9.0,wherein the components are combined with nuclease-free water; andproviding a pair of PCR primers wherein one primer of the pair of PCR primers comprises the nucleic acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5, and the other primer of the pair of PCR primers comprises the nucleic acid sequence of SEQ ID NO: 3 or SEQ ID NO: 6. 5. The method of claim 4, wherein the pKa of the buffer is within about 1.0 unit of the pH at an ambient temperature. 6. The method of claim 4, further comprising contacting the biological sample with the composition and performing a thermal cycling reaction on the mixture. 7. The method of claim 4, wherein the one or more chelating agents comprise ethylene glycol tetraacetic acid, hydroxyethylethylenediaminetriacetic acid, diethylene triamine pentaacetic acid, N,N-bis(carboxymethyl)glycine, ethylenediaminetetraacetic, citrate anhydrous, sodium citrate, calcium citrate, ammonium citrate, ammonium bicitrate, citric acid, diammonium citrate, potassium citrate, magnesium citrate, ferric ammonium citrate, lithium citrate, or any combination thereof. 8. The method of claim 4, wherein the one or more PCR osmolarity agents comprise N,N,N-trimethylglycine (betaine), dimethyl sulfoxide (DMSO), foramide, glycerol, nonionic detergents, deoxyinosine, glycerine, 7-deaza deoxyguanosine triphosphate, sodium hydroxide, polyethylene glycol, tetramethylammonium chloride, or any combination thereof. 9. The method of claim 4, wherein the one or more albumins comprises bovine serum albumin, human serum albumin, goat serum albumin, mammalian albumin or any combination thereof. 10. The method of claim 4, wherein the one or more salts comprise potassium chloride, potassium glutamate, magnesium chloride, magnesium sulfate, and any combination thereof. 11. The method of claim 4, wherein the one or more buffers comprise tris(hydroxymethyl) aminomethane (Tris), citrate, 2-(N-morpholino)ethanesulfonic acid (MES), N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 1,3-bis(tris(hydroxymethyl) methylamino)propane (Bis-Tris), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), N,N-bis(2-hydroxyethyl) glycine (Bicine), N-[tris(hydroxymethyl)methyl]glycine (Tricine), N-2-acetamido-2-iminodiacetic acid (ADA), N-(2-acetamido)-2-aminoethanesulfonic acid (ACES), piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), bicarbonate, phosphate, or any combination thereof. 12. The method of claim 1, further comprising a reverse transcriptase. 13. The method of claim 4, further comprising a reverse transcriptase. 14. The method of claim 1, wherein the thermostable polymerase is a Platinum Taq polymerase, Taq polymerase, a high fidelity polymerase, a Pfu polymerase, a hot start polymerase, or a next gen polymerase. 15. The method of claim 1, wherein the one or more dyes are selected from the group consisting of fluorescein, 5-carboxy-X-rhodamine and ROX. 16. The method of claim 4, wherein the one or more dyes are selected from the group consisting of fluorescein, 5-carboxy-X-rhodamine and ROX. 17. The method of claim 1, wherein the pH of the composition is from about 6.5 to about 7.5. 18. The method of claim 1, wherein the pKa of the buffer is within 0.5 of the pH of the buffer at ambient temperature. 19. The method of claim 1, wherein the pKa of the buffer is within 0.2 of the pH of the buffer at ambient temperature. 20. The method of claim 1, wherein the pair of PCR primers is present in the composition at a concentration of about 0.5 μM to about 50 μM. 21. The method of claim 1, wherein the microorganism is bacteria, virus, fungus or a parasite. 22. The method of claim 21, wherein the bacteria is mycobacteria. 23. The method of claim 21, wherein the virus is influenza virus. 24. The method of claim 23, wherein the influenza virus is H1N1, H2N2, H3N3, or H5N1. 25. The method of claim 1, further comprising a control nucleic acid present in the concentration at a concentration of about 1 fg to about 1 ng, wherein the control nucleic acid provides a qualitative or quantitative measure of PCR amplification. 26. The method of claim 25, wherein the control nucleic acid comprises the sequence of SEQ ID NO 8, the sequence of SEQ ID NO 12 or the sequence of SEQ ID NO 21. 27. The method of claim 1, further comprising a detection probe that binds to a PCR amplified nucleic acid sequence that is specific to the microorganism. 28. The method of claim 1, which comprises about 50 mM of TRIS; about 70 mM of potassium chloride; about 3 mM of magnesium sulfate; about 45 mM of betaine; about 0.03 μg/mL of bovine serum albumin; about 0.1 mM of EDTA; about 0.05 μM of dye; about 8 μM of the pair of PCR primers. 29. The method of claim 27, wherein the detection probe is a Mycobacterium-specific sequence and comprises the sequence of SEQ ID NO 4 or SEQ ID NO 7. 30. The method of claim 5, wherein the pH of the composition is from about 6.5 to about 7.5. 31. The method of claim 5, wherein the pKa of the buffer is within 0.5 of the pH at ambient temperature. 32. The method of claim 5, wherein the pKa of the buffer is within 0.2 of the pH at ambient temperature. 33. The method of claim 4, wherein the microorganism is bacteria, virus, fungus or a parasite. 34. The method of claim 33, wherein the bacteria is mycobacteria. 35. The method of claim 33, wherein the virus is influenza virus. 36. The method of claim 33, wherein the influenza virus is H1N1, H2N2, H3N3, or H5N1. 37. The method of claim 4, further comprising a control nucleic acid present in the concentration at a concentration of about 1 fg to about 1 ng, wherein the control nucleic acid provides a qualitative or quantitative measure of PCR amplification. 38. The method of claim 37, wherein the control nucleic acid comprises the sequence of SEQ ID NO 8, the sequence of SEQ ID NO 12 or the sequence of SEQ ID NO 21. 39. The method of claim 4, further comprising a detection probe that binds to a PCR amplified nucleic acid sequence that is specific to the microorganism. 40. The method of claim 39, wherein the detection probe is a Mycobacterium-specific sequence and comprises the sequence of SEQ ID NO 4 or SEQ ID NO 7. 41. The method of claim 4, which comprises about 50 mM of TRIS; about 70 mM of potassium chloride; about 3 mM of magnesium sulfate; about 45 mM of betaine; about 0.03 μg/mL of bovine serum albumin; about 0.1 mM of EDTA; about 0.05 μM of dye; about 8 μM of the pair of PCR primers. 42. A method of providing for detection of a microorganism in a biological sample containing nucleic acids forming a PCR-ready composition comprising: providing a composition containing: a mix of deoxynucleotide tri phosphates comprising about equivalent amounts of dATP, dCTP, dGTP and dTTP, collectively present in the composition at a concentration of about 0.1 mM to about 10 mM;a chelating agent present in the composition at a concentration of about 0.01 mM to about 1 mM;an osmolarity agent present in the composition at a concentration of about 1 mM to about 1 M;an albumin protein present in the composition at a concentration of about 5 ng/ml to about 250 ng/ml;at least two salts together present in the composition at a concentration of about 50 mM to about 1 M;a pair of PCR primers wherein one primer of the pair of PCR primers comprises the nucleic acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5, and the other primer of the pair of PCR primers comprises the nucleic acid sequence of SEQ ID NO: 3 or SEQ ID NO: 6;a dye at a concentration of from about 0.01 μM to about 1 μM; anda buffer present in the composition at a concentration of about 100 mM to about 1 M and with a pH of about 6.5 to about 9.0,combining the composition with nuclease-free water to form the PCR-ready composition; andcombining the PCR-ready composition with nucleic acids of the biological sample. 43. The method of claim 42, wherein the pH of the composition is from about 6.5 to about 7.5. 44. The method of claim 42, wherein the pKa of the buffer is within 1.0 unit of the pH at ambient temperature. 45. The method of claim 44, wherein the pKa of the buffer is within 0.5 units of the pH at ambient temperature. 46. The method of claim 42, wherein the PCR-ready composition contains as the chelating agent EDTA, EGTA, HEDTA, DTPA, NTA and/or APCA, as the osmolarity agent betaine, as the two salts a potassium salt and a magnesium salt, as the dye ROX, and as the buffer HEPES, Tris, MOPS and/or PIPES. 47. The method of claim 46, wherein the PCR-ready composition contains the chelating agent at a concentration of from about 0.1 mM to 1 mM, the osmolarity agent at a concentration of from about 10 mM to 50 mM, the potassium salt at a concentration of from about 50 mM to 100 mM, the magnesium salt at a concentration of from about 1 mM to 10 mM, the dye at a concentration of from about 0.1 μM to 1 μM, and the buffer at a concentration from about 50 mM to 100 mM. 48. The method of claim 42, further comprising a thermostable polymerase. 49. The method of claim 48, wherein the thermostable polymerase is present in an amount from about 0.05 U to about 1 U. 50. The method of claim 45, wherein the pKa of the buffer is within about 0.2 units of the pH at a selected temperature. 51. The method of claim 4, wherein the thermostable polymerase is present in the composition in an amount of from about 0.05 U to about 1 U. 52. The method of claim 4, wherein the mix of deoxynucleotide tri phosphates are collectively present in the composition at a concentration of from about 0.1 mM to about 1 mM. 53. The method of claim 4, wherein the one or more chelating agents are present in the composition at a concentration of from about 0.01 mM to about 1 mM. 54. The method of claim 4, wherein the one or more PCR osmolarity agents are present in the composition at a concentration of from about 1 mM to about 1 M. 55. The method of claim 4, wherein the one or more albumins are present in the composition at a concentration of from about 5 ng/ml to about 100 ng/ml. 56. The method of claim 4, wherein the one or more salts are collectively present in the composition at a concentration of from about 50 mM to about 1 M. 57. The method of claim 4, wherein the one or more dyes are present in the composition at a concentration of from about 0.01 μM to about 1 μM. 58. The method of claim 4, wherein the one or more buffers are present in the composition at a concentration of from about 1 mM to about 1 M.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (149)
Liav Avraham ; Hansjergen Joyce Anne ; Shimasaki Craig David, 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinic.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis apparatus.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis apparatus.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis process.
Gayral, Jean Pierre; Picard, Francois; Boissinot, Maurice; Bastien, Martine, Biological reagents and methods to verify the efficiency of sample preparation and nucleic acid amplification and/or detection.
Monthony James F. (Baltimore MD) Stitt David T. (Parkton MD) Gosnell C. Michael (Fallston MD) Stewart Shannon D. (Stewartstown PA), Biological sample collection and transport device.
Bair, Jr., Robert Jackson; Heath, Ellen M.; Meehan, Heather; Paulsen, Kim Elayne; Wages, Jr., John M., Compositions and methods for using a solid support to purify RNA.
Cerutti Peter A. (Poly/Lausanne CHX) Bressoud Albric (Lausanne CHX), Detection of influenza a virus by polymerase chain reaction (PCR) preceded by reverse transcription of a region of the v.
Whiteley Norman M. (San Carlos CA) Hunkapiller Michael W. (San Carlos CA) Glazer Alexander N. (Orinda CA), Detection of specific sequences in nucleic acids.
Doyle Michael V. (Oakland CA) Newell Arthur D. (Orinda CA) Nunberg Jack H. (Oakland CA) White Thomas J. (Oakland CA), Human IL-2 as a vaccine adjuvant.
Hunter Kenneth W. (4401 Dresden St. Kensington MD 20895) Fischer Gerald W. (10748 Wayridge Dr. Gaithersburg MD 20879), Human monoclonal antibody reactive with polyribosylribitol phosphate.
Heller Michael J. (Encinitas CA), Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to donor energy transfe.
Sette, Alessandro; Sidney, John; Southwood, Scott; Vitiello, Maria A.; Livingston, Brian D.; Celis, Esteban; Kubo, Ralph T.; Grey, Howard M.; Chesnut, Robert W., Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions.
Liav Avraham ; Shimasaki Craig D. ; Maher James F. ; Clinkscales C. Worth ; Roark Michael D., Kit for visually detecting the presence of a clinical specimen.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Liav Avraham (Denver CO) Maher James F. (Broken Arrow OK) Shimasaki Craig D. (Tulsa OK) Clinkscales C. Worth (Tulsa OK) Roark Michael D. (Owasso OK), Method for visually detecting the presence of a virus in a clinical specimen.
Reece Phillip A.,AUX ; Wu Wen-Yang,AUX ; Jin Betty,AUX ; Krippner Guy Y.,AUX ; Watson Keith Geoffrey,AUX, Method of detection of influenza virus and compounds for use therein.
Turner Gregory A. (Independence MO) Maher James F. (Broken Arrow OK) Clinkscales C. Worth (Tulsa OK) Roark Michael D. (Owasso OK), Methods for diagnosing human influenza and 4-position modified chromogenic N-acetylneuraminic acid substrated for use th.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Monthony James F. (Baltimore MD) Stitt David T. (Parkton MD) Gosnell C. Michael (Fallston MD) Stewart Shannon D. (Stewartstown PA), Polyurethane biological sample collection and transport device and its use.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Boom Willem R. (Amsterdam NLX) Adriaanse Henritte M. A. (Arnhem NLX) Kievits Tim (The Hague NLX) Lens Peter F. (Amsterdam NLX), Process for isolating nucleic acid.
Fell ; Jr. H. Perry (Redmond WA) Folger-Bruce Kim R. (Seattle WA) Yarnold Susan M. (Seattle WA), Production of chimeric antibodies by homologous recombination.
Crawford Jack T. (Atlanta GA) Eisenach Kathleen D. (Little Rock AR) Cave M. Donald (Little Rock AR) Bates Joseph H. (Little Rock AR), Repetitive DNA sequence specific for mycobacterium tuberculosis to be used for the diagnosis of tuberculosis.
Crawford Jack T. (Atlanta GA) Eisenach Kathleen D. (Little Rock AR) Cave M. Donald (Little Rock AR) Bates Joseph H. (Little Rock AR), Repetitive DNA sequence specific for mycobacterium tuberculosis to be used for the diagnosis of tuberculosis.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Judd Amrit K. (Belmont CA) Bucher Doris J. (New York NY) Popple Steven W. (Brooklyn NY), Synthetic peptides for diagnosis and prevention of influenza virus infection and their use.
Picard,Francois J.; Menard,Christian, Universal method and composition for the rapid lysis of cells for the release of nucleic acids and their detection.
van Scharrenburg, Gustaaf J. M.; Brands, Rudi; de Haan, Lolke; Verweij, Willem Ronald; Wilschut, Jan C.; Agsteribbe, Etienne, Vaccines with an LTB adjuvant.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.